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ignificance of QRS Complex
uration in Patients With Heart Failure
mir Kashani, MS, MD,* S. Serge Barold, MD, FACC†
ew Haven, Connecticut; and Tampa, Florida
Prolongation of QRS (120 ms) occurs in 14% to 47% of heart failure (HF) patients. Left
bundle branch block is far more common than right bundle branch block. Left-sided
intraventricular conduction delay is associated with more advanced myocardial disease, worse
left ventricular (LV) function, poorer prognosis, and a higher all-cause mortality rate
compared with narrow QRS complex. It also predisposes heart failure patients to an increased
risk of ventricular tachyarrhythmias, but the incidence of cardiac or sudden death remains
unclear because of limited observations. A progressive increase in QRS duration worsens the
prognosis. No electrocardiographic measure is specific enough to provide subgroup risk
categorization for excluding or selecting HF patients for prophylactic implantable
cardioverter-defibrillator (ICD) therapy. In ICD patients with HF, a wide underlying QRS
complex more than doubles the cardiac mortality compared with a narrow QRS complex.
There is a high incidence of an elevated defibrillation threshold at the time of ICD
implantation in patients with QRS 200 ms. Mechanical LV dyssynchrony potentially
treatable by ventricular resynchronization occurs in about 70% of HF patients with left-sided
intraventricular conduction delay, a fact that would explain the lack of therapeutic response
in about 30% of patients subjected to ventricular resynchronization according to standard
criteria relying on QRS duration. The duration of the basal QRS complex does not reliably
predict the clinical response to ventricular resynchronization, and QRS narrowing after
cardiac resynchronization therapy does not correlate with hemodynamic and clinical improve-
ment. Mechanical LV dyssynchrony is best shown by evolving echocardiographic techniques
(predominantly tissue Doppler imaging) currently in the process of standardization. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.071Coll Cardiol 2005;46:2183–92) © 2005 by the American College of Cardiology Foundation
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Is long ago as 1962, there was speculation regarding the
rognosis of QRS prolongation in patients with heart failure
HF) (1). Thereafter, a few studies reported mortality rates
f 50% to 70% (over 50 to 60 months of follow-up) in
atients with HF with left ventricular (LV) conduction
elay (2–4) but others could not corroborate these findings
5). The conflicting results of these older studies may have
een related to the prevailing unstandardized diagnosis and
anagement of HF. Since then, important therapeutic
dvances have generated new questions about the signifi-
ance of QRS prolongation in patients with HF.
NCIDENCE
rolongation of QRS (120 ms) occurs in 14% to 47% of
atients with HF (Table 1) and is generally accepted as
ccurring in approximately 30% (4,6–19). Left bundle
ranch block (LBBB) occurs more commonly than right
undle branch block (RBBB) (25% to 36% vs. 4% to 6%,
espectively) (13,20,21). There are a number of possible
auses for the varying reported incidence of QRS prolon-
ation in the HF population. The definition of QRS
From the *Section of Cardiology, Yale University School of Medicine, New Haven,
onnecticut; and the †Division of Cardiology, University of South Florida College of
edicine, Tampa, Florida.y
Manuscript received November 1, 2004; revised manuscript received December 26,
004, accepted January 12, 2005.rolongation is not uniform; some studies set the limit at
20 ms and others at 150 ms. No two studies used the
ame methodology to measure QRS duration (Table 1)
4,6–11,13,14,17). Indeed, a variety of methodologies were
pplied to measure QRS duration: computer-reported mea-
urements, average of several complexes, or widest complex
n electrocardiogram (ECG). Some reports either were
ague or simply did not state how QRS durations were
easured.
Although all of the studies in Table 1 were conducted in
atients with HF, there is obviously some heterogeneity
mong studied populations. Some patients with HF may
ot have had true LV systolic dysfunction, particularly in
tudies in which the LV ejection fraction (LVEF) was not
etermined. Some study populations consisted of patients
ith advanced HF (11,15), others involved HF patients
ith implanted defibrillators (a group that generally has
ore severe disease than the populations in most other
eports) (14), whereas others focused on clinically stable
utpatients (13).
V FUNCTION AND CLINICAL STATUS
rolongation of QRS (120 ms) is a significant predictor of
V systolic dysfunction in patients with HF (4,8,10,11,22).
n contrast, the significance of QRS prolongation has not
et been evaluated in HF with a normal LVEF and diastolic
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QRS Duration in Heart Failure December 20, 2005:2183–92ysfunction. In patients with HF, an inverse correlation
xists between QRS prolongation and LVEF (Table 1)
4,8,10,11,13,18). In a study of nearly 3,500 patients with
F, Shenkman et al. (7) found a stepwise increase in the
revalence of systolic LV dysfunction as QRS complex
uration increased progressively above 120 ms. A more
ecent study conducted in 343 patients with HF reported
VEF of 41%, 36%, 29%, and 25% in patients with QRS
urations of 100 ms, 100 to 119 ms, 120 to 149 ms, and
150 ms, respectively (10). These observations in patients
ith HF are in keeping with the findings of Murkofsky et
l. (23), who analyzed 226 patients (without typical bundle
ranch block, pacemaker, or stated HF) referred for radio-
uclide exercise ventriculography. The study indicated a
igh likelihood of an abnormal LVEF 45% with a QRS
0.10 s. The specificity increased for each 0.01-s increase in
RS duration so that it increased to over 99% with a QRS
ncrement from 0.10 s to 0.12 s (23).
Moderate or severe mitral regurgitation was seen in 8%
nd 20% of patients with HF with QRS 120 ms and
120 ms, respectively. Increasing QRS duration was also
ssociated with more severe tricuspid regurgitation (10).
ROGRESSION OF QRS DURATION
s a rule, QRS duration increases as LV function worsens
4,8,10,13,24). One HF study indicated that the incidence
f QRS prolongation (120 ms) increased from 10% to
2% and 53% when patients moved from New York Heart
ssociation (NYHA) functional class I to class II and III,
espectively (24). In a study of 5,517 outpatients with HF,
RS prolongation was seen more frequently in patients
ith advanced NYHA functional class (32.8% of patients
ith complete LBBB vs. 26.4% without complete LBBB
ere in NYHA class III to IV) (21). Gasparini et al. (25)
eported similar findings in a study of 158 patients with
evere HF undergoing biventricular pacemaker implanta-
ion: 86% of patients with QRS 150 ms were in NYHA
unctional class III or IV versus 60% of patients with QRS
150 ms (p  0.002). According to Xiao et al. (26), who
nalyzed a series of patients with dilated cardiomyopathy of
Abbreviations and Acronyms
CI  confidence interval
CRT  cardiac resynchronization therapy
ECG  electrocardiogram
HF  heart failure
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
LBBB  left bundle branch block
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RBBB  right bundle branch block
VT  ventricular tachycardiaixed etiology admitted to a tertiary center (not necessarily tor a procedure), QRS prolongation progresses at an annual
ate of 5 ms in a population presumed to have HF and who
eceived appropriate therapy for it, although HF diagnosis was
ot specifically indicated by the investigators. Larger increases
n QRS duration occur in patients with early mortality. In
he study by Xiao et al. (26), the time from reaching a QRS
f 160 ms to death was 9.8 18 months in patients without
n implanted pacemaker versus 31  16 months in patients
ith a pacemaker (26). The significance of these observa-
ions is unclear unless one postulates that ventricular pacing
as intermittent because impaired LV dysfunction is related
o the cumulative percent of ventricular pacing (27–30).
One study of 56 patients with symptomatic HF (followed
p from 180 to 7,660 days; mean, 1,755 days) and necropsy-
roven idiopathic dilated cardiomyopathy documented an
ncrease in QRS duration from an average of 0.10 s to an
verage of 0.13 s in 76% of patients before death (20). These
esults are consistent with those of other reports in cardio-
yopathy (ischemic or non-ischemic) and patients with HF
dentifying QRS prolongation as a poor prognostic indicator
4,26).
ORTALITY
atients with HF with QRS prolongation have higher all-
ause mortality and possibly a higher incidence of sudden
eath (or cardiac death) than those with narrow QRS
omplexes (4,9,11,13,31,32) (Table 2). In fact, mortality
ates progressively increase as intraventricular conduction
elay increases. In one study, QRS 0.12 s, QRS 0.12 to
.16 s, and QRS 0.16 s correlated with 20%, 36%, and
8% mortality at 36 months, respectively (9).
Kalra et al. (8) investigated the optimal QRS duration
hat separates patients with HF into those with a relatively
enign versus a poor prognosis (i.e., increased mortality or
eart transplantation). Patients with a QRS 0.12 s had a
hree-fold increased risk for the combined end point of
eath or transplantation. Also, five-year survival was signif-
cantly lower in this patient population when compared with
atients with HF with QRS 0.12 s (47% vs. 84%; p 
.0001) (8).
In patients with B-type natriuretic peptide levels 400
g/ml, QRS prolongation was found to be a significant
nivariate and multivariate predictor of all-cause death,
ardiac death, and pump failure death (33). In a study of 82
atients with HF and dilated cardiomyopathy, change in
RS duration over time (0.5 ms/month) was a multivar-
ate predictor of cardiac death or need for heart transplant at
ne year (34). In another study, QRS duration was the only
lectrocardiographic parameter with independent prognos-
ic value for adverse outcomes (22). In 100 patients with HF
eferred for cardiac transplantation, 55% of patients with
RS duration 0.12 s (vs. 24% with QRS 0.12 s) went
n to transplantation or death (11). The time course of the
ransplantation patients was not stated.
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December 20, 2005:2183–92 QRS Duration in Heart FailureIn a substudy of the Multicenter Unsustained Tachycar-
ia Trial (MUSTT) (35), Zimetbaum et al. (36) analyzed
CGs from 1,638 patients (approximately 70% had HF)
ho did not receive antiarrhythmic drugs or implantable
ardioverter-defibrillators (ICDs). Seventy-five percent of
he patients with LV hypertrophy had clinical congestive
F, and so did 62% of those without LV hypertrophy. The
rimary end point was cardiac arrest or arrhythmic death.
ultivariate analyses identified nonspecific intraventricular
onduction delay (defined as QRS 0.11 s but morpholog-
cally different from LBBB or RBBB) as a predictor of
rrhythmic or cardiac arrest (hazard ratio [HR], 1.44; 95%
onfidence interval [CI], 1.11 to 1.88) and total (HR, 1.47;
I, 1.22 to 1.78) mortality. The LBBB was also a signifi-
ant predictor of arrhythmic (HR, 1.49; CI, 1.02 to 2.17)
able 1. Incidence of QRS Prolongation in Heart Failure Patien
Study Year
No. of
Patients
LVEF
(%)
QRS >120
(%)
ader et al. (6) 2004 104 31  9* 47
34 with QR
140 ms
andhu et al. (10) 2004 343 25  18† 24
reudenberger et al. (11) 2004 100 19  7‡ 34
hen et al. (12) 2004 1,129 38  14 20 with QR
130 ms
aldasseroni et al. (13) 2003 5,517 NS 38
ode-Schnurbus et al. (14) 2003 165 33  14* NS
alizio et al. (15) 2003 200 NS 54
rimm et al. (16) 2003 566 31  10* 39
earney et al. (17) 2003 184 24  1† NS
u et al. (18) 2003 112 38  10* 40
uliano et al. (4) 2002 669 24  8‡ 43
alra et al. (8) 2002 155 23  9* 47
henkman et al. (7) 2002 3,471 NS 21
arwell et al. (19) 2000 721 37  14* 25
hamim et al. (9) 1999 241 28* 38
everal articles included in the table did not provide standard deviations of data. LVE
ide QRS duration compared with LVEF in patients with narrow QRS duration. *
ubgroups but not from the entire group; †only patients with QRS 150 ms; ‡only
ECG  electrocardiogram; HF  heart failure; IVCD  intraventricular conducti
not stated; QRS measurement  method used to determine QRS duration; RBBnd total (HR, 1.61; CI, 1.26 to 2.08) mortality. The sBBB, however, was not associated with increased arrhyth-
ic or total mortality (36).
Prolongation of QRS and severe cardiomyopathy (de-
ned as LVEF 30%) have an additive effect on mor-
ality. The highest mortality rates are seen in patients
ith HF with QRS prolongation and LVEF 35%
econdary to both ischemic and non-ischemic etiologies
4,7).
In 1995, Silverman et al. (32) reported that QRS prolon-
ation had a different prognostic value in patients with
hronic HF with non-ischemic versus ischemic cardiomy-
pathy. They found that a prolonged QRS carried a
ignificantly worse prognosis only in patients with non-
schemic cardiomyopathy. These results are at variance from
he observations of Iuliano et al. (4), who found no
orrelation With Left Ventricular Function
QRS >150 ms
(%) QRS Measurement
LVEF and QRS
Correlation (p Value)
NS Interpreted by two NS
independent blinded
observers
12 MUSE electrocardiographic
system analysis of
intervals
Yes (0.0001)
NS Interpreted by two blinded
cardiologists
Yes (0.04)
6 NS
58% LBBB
22% RBBB
20% IVCD
Only patients with
LVEF 35% were
analyzed. Yes with
QRS 130 ms
(0.02)
NS Measured by a single
cardiologist at each
participating center using
a standardized format
Yes (0.001)
16 Mean of three complexes in
leads V3 to V6
Trend only
34 NS NS
24 NS NS
29 Reynolds Medical
Pathfinder system by
independent blinded staff
–
No difference in groups
QRS 150 vs. 150
ms (0.08)
NS NS Yes (0.001)
NS ECG read by computer and
cardiologist
Yes (0.001)
19 Average of three readings
from lead V2 with
electronic calipers
Yes (0.001)
8 Mean duration in all 12
leads as measured by
computer
NS
NS NS NS
NS Average of three readings
from lead V2 with
electronic calipers
Trend only
QRS correlation indicates the presence of a statistically significant lower LVEF with
LVEF of all patients regardless of QRS duration; some studies provided LVEF of
ts with QRS 120 ms.
ay; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; NS
ight bundle branch block; Year  year of publication.ts: C
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QRS Duration in Heart Failure December 20, 2005:2183–92ortality or sudden death in patients with non-ischemic
ardiomyopathy and QRS 0.12 s versus QRS 0.12 s.
owever, Iuliano et al. (4) reported a significantly higher
ll-cause and sudden-death mortality rate in patients with
F with ischemic cardiomyopathy and a longer QRS
uration. Comparing the groups with QRS 0.12 s versus
RS0.12 s (median follow-up, 45 months), the mortality
as 51% vs. 34% and the sudden death rate was 25% vs.
7%, respectively (4).
ENTRICULAR TACHYCARDIA
he aforementioned data raise the question of whether
entricular tachycardia (VT) accounts for the increased
ortality in patients with HF with QRS prolongation. A
ide QRS complex predisposes patients with HF to bundle
ranch re-entrant VT (bundle branch to bundle branch), a
elatively rare arrhythmia that occurs predominantly in
atients with dilated cardiomyopathy and a wide QRS
omplex in the form of LBBB or a nonspecific intraventric-
lar conduction delay resembling LBBB (37–39). Although
any patients with this form of VT receive ICDs because of
he risk of other types of VT, the diagnosis of bundle branch
e-entry VT is important because it can be easily eliminated
y ablation of the right bundle branch.
Horwich et al. (40) studied 777 patients using electro-
hysiologic studies for assessment of VT inducibility. The
ercentage of patients with HF was not specified. Sustained
onomorphic VT was induced in 49% and 23% (p
0.0001) of patients with QRS 120 ms and 120 ms,
espectively, with bundle branch re-entrant VT in a minor-
ty, and multivariate analysis showed that QRS duration was
n independent risk factor for VT inducibility. In fact, the
isk of inducible sustained monomorphic VT increased by
.4% for each 1 ms increase in QRS duration. This suggests
hat intraventricular conduction delay with or without a
carred myocardium can act as a substrate for re-entrant VT.
CD TRIALS
ulticenter Automatic Defibrillator Implantation Trial
I (MADIT-II). In MADIT-II, Moss et al. (41,42) stud-
ed the effect of prophylactic cardioverter-defibrillator im-
lantation in patients with NYHA functional class I to III,
VEF 30%, and a myocardial infarction one or more
onths before enrollment in the study. The patients were
haracterized as having substantial LV dysfunction (mean
aseline LVEF was about 23%), and 70% were in NYHA
unctional class I or II HF. The actual incidence of clinical
F was not mentioned, but it was probably common in this
ighly selected patient population. We believe that the
ADIT-II observations can be extrapolated to the general
F patient population. Three clinically relevant categories
f QRS duration (0.12 s, 0.12 to 0.15 s, 0.15 s) were
nalyzed. There was a trend toward better reduction in
ortality with ICD therapy in patients with the wider QRScomplexes, but it was not statistically significant. Moss et al.Ta
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December 20, 2005:2183–92 QRS Duration in Heart Failure42) then extended their analysis of the MADIT II data to
nclude each of six QRS durations (0.09 s, 0.09 to 0.10 s,
.11 to 0.12 s, 0.13 to 0.14 s, 0.15 to 0.16 s, 0.16 s).
imilar HRs (mortality reduction) were found across all six
RS durations, suggesting that QRS duration is not an
ffective risk stratification factor for ICD therapy in the
ADIT II population.
In addition to the reduction in mortality results, the
ADIT II investigators also noted a slightly higher rate of
ospitalization for HF in the ICD group compared with
ontrol patients (19.8% vs. 14.9%, respectively) (41). The
igher hospitalization rate might have been attributable to
echanical LV dyssynchrony induced by chronic right
entricular pacing (27,28,30). Indeed, preliminary data from
he MADIT II trial suggested that HF is related to the
ercentage of ventricular pacing (43), hence the importance
f minimizing right ventricular pacing, especially in patients
ho do not need it.
udden Cardiac Death in Heart Failure Trial (SCD-
eFT). The SCD-HeFT was a randomized, placebo-
ontrolled study designed to determine whether amiodarone
r a single-chamber ICD programmed to shock only (no
ack-up pacing) would reduce all-cause mortality when
ompared with placebo (double-blind to drug therapy) in
atients with dilated cardiomyopathy (ischemic or nonisch-
mic), NYHA functional class II and III HF, and LV
ysfunction (LVEF 35%) (44–46). A total of 2,521
atients were enrolled with randomization to ICD (n 
29), amiodarone therapy (n  845), or placebo (n  847).
he median age of patients was 60 years (range, 19 to 90
ears). Unlike the MADIT II trial, the SCD-HeFT study
ncorporated patients with nonischemic cardiomyopathy as
ell as those with ischemic HF. Most importantly, both
atient groups were found to benefit from ICD therapy.
hen stratifying the ECG data in the ICD versus placebo
roups, ICD therapy was associated with a significant
eduction in the risk of mortality compared with placebo,
egardless of the ECG measure, including QRS duration
120 ms or 120 ms. Another analysis found that al-
hough ICD shock rates were highest in patients with a
onger QRS duration, patients with a narrow QRS also
xperienced a significant number of shocks, suggesting that
reatment is warranted for this group also at higher risk.
A subset of MADIT II-like patients enrolled in SCD-
eFT (approximately 80% of the ischemic patients in
CD-HeFT met MADIT II criteria) showed the same
eduction in mortality with ICD therapy regardless of QRS
uration. Thus, for the SCD-HeFT population, no ECG
easure seems to be specific enough to provide subgroup
isk categorization for either excluding or selecting patients
or ICD therapy.
On the basis of the MADIT II and SCD-HeFT data, the
enters for Medicare and Medicaid recently abandoned
heir restrictions on Medicare reimbursement for ICDs in
atients with a prior myocardial infarction and LVEF of
0% or less and QRS duration 120 ms (47). oDespite the above considerations, a wide QRS complex
emains an important prognostic marker in ICD patients
ith HF. In a recent study over 24 months in ICD patients
ith HF, those with a wide underlying QRS complex
howed more than double the cardiac mortality than those
ith a narrow QRS complex (14). In view of two recent
eta-analyses suggesting that resynchronization decreases
ortality (48,49), it is tempting to postulate that the
ortality in ICD patients with a wide QRS complex might
ave been reduced by upgrading their devices to biventricu-
ar ICDs. The association of a wide QRS complex with
ore advanced disease in ICD patients is also reflected in
he high incidence of an elevated defibrillation threshold at
he time of ICD implantation in patients with QRS 200
s, requiring the use of high-output ICDs (50).
ARDIAC RESYNCHRONIZATION
rowing experience with cardiac resynchronization therapy
CRT) has highlighted the limitations of a wide QRS
omplex as a surrogate for mechanical LV dyssynchrony
51–83). Widening of the QRS complex was a major entry
riterion in the recent trials and other studies of biventricu-
ar pacing in patients with HF with LVEF35% (Table 3).
he QRS duration in the major trials ranged from 120 to
150 ms (63,67,77,84).
lectrocardiographic parameters. QRS DURATION AND
ECHANICAL DYSSYNCHRONY. Barring a very wide spon-
aneous QRS complex, which probably increases the likeli-
ood of associated mechanical LV dyssynchrony (54), the
atter is not necessarily related to electrical dyssynchrony
udged by QRS duration (Table 3). Indeed, the correlation
s weak. Some patients with a wide QRS and a severely
epressed LVEF may show no area of substantial mechan-
cal delay (85). Thus, the predictive value of the basal QRS
omplex is poor for responders and nonresponders. (Table 3:
esponders consist of patients who had a statistically signif-
cant decrease in NYHA functional class (or equivalent)
nd/or increase in LVEF (or equivalent), and nonre-
ponders consist of those who showed no change in these
wo indexes). This may explain why 20% to 30% of the
atients in the major trials did not have a response to CRT
86–89). In this respect, Bleeker et al. (85) evaluated the
ole of the QRS complex as a marker of mechanical LV
yssynchrony (based on septal-to-lateral conduction delay)
n 90 patients with severe HF (LVEF 35%, NYHA
unctional class III to IV). Severe mechanical LV dyssyn-
hrony was defined as an electromechanical delay 60 ms
etween the septum and the lateral wall based on tissue
oppler imaging, the technique that has thus far been used
he most frequently to determine LV mechanical dyssyn-
hrony. The 60 ms value was based on previous observa-
ions that a delay 60 ms between the peak systolic velocity
f the septum and lateral wall was highly predictive of
esponse to CRT. Severe mechanical LV dyssynchrony was
bserved in 27% of the patients with a narrow QRS complex
Table 3. Biventricular Pacing and QRS Duration
Study Year
No. of
Patients*
Form of
Prolonged
QRS
Mean
Follow-Up
(months)
Mean QRS
Before CRT
(ms)
Mean QRS After
CRT (ms)
Previous QRS vs.
QRS After CRT†
p Value
Clinical and
Hemodynamic
Improvement
Relationship
Between QRS
Shortening
and Clinical
Improvement
Correlation of
Spontaneous
QRS Duration
and Clinical
Response
Bonanno et al. (51) 2004 37 NS 8  8 189  35 162  13 0.001 NYHA2, LVEF1 NS NS
Molhoek et al. (52) 2004 61 100% LBBB 6 177  30 161  24 0.01 NYHA2, LVEF NS No No
Penicka et al. (53) 2004 49 100%
“LBBB-like”
6 NYHA2, LVEF1 No Yes
Responders 27 190  30 152  37 0.01 Yes No —
Non-responders 22 171  27 154  30 0.01 No No —
Yu et al. (54) 2004 58 No No
QRS 120 to 150 ms 27 15% LBBB
85% IVCD
3 134  14 NS NS NYHA2, LVEF1
QRS 150 ms 31 87% LBBB
13% IVCD
3 172  22 NS NS NYHA2, LVEF1
Achilli et al. (55) 2003 52 NS 18  9 151  31 124  10 0.001 NYHA2, LVEF1 NS NS
Bax et al. (56) 2003 22 100% LBBB 3 172  33 158  26 0.05 NYHA2, LVEF1 NS NS
Chan et al. (57) 2003 63 NS 3 182  31 151  25 0.001 NYHA2, LVEF1 Yes NS
Duncan et al. (58) 2003 34 IVCD 12 172  19 159  33 0.04 NYHA2, LVESD2,
LVEDD2, LVEF NS
NS NS
Gasparini et al. (59) 2003 104 85% LBBB
8% RBBB
7% Other
9 165  37 143  38 0.013 NYHA and LVEF
improved but statistical
data ns
NS NS
Gasparini et al. (25) 2003 158 NS 11 NS No
QRS 110 to 150 ms 30 NS 130  15 133  15 NS NYHA2, LVEF1 NS —
QRS 150 ms 128 NS 184  22 152  17 0.0001 NYHA2, LVEF1 NS —
Toussaint et al. (60) 2003 34 100% LBBB 20  7 179  18 159  16 0.0001 NYHA2, LVEF1 No No
Young et al. (61) 2003 187 13% RBBB
Rest NS
6 165  22 20 0.001 NYHA2 Trend 2LV
Vols, LVEF NS
NS No
Yu et al. (62) 2003 30 57% LBBB
43% IVCD
3 167  33 145  25 0.001 NYHA2, LVEF1 No No
Abraham et al. (63) 2002 228 NS 6 167  21 Median decrease
of 20 ms
0.001 NYHA2, LVEF1 NS No
Ansalone et al. (64) 2002 31 100% LBBB 1 week
and 1
month
160  27 123  24 0.001 NYHA2, LVEF1 No NS
Martinelli-Filho et al. (65) 2002 24 100% LBBB 24.5 180.7 177.4 ns NYHA2, LVEF1 NS NS
Gras et al. (66) 2002 103 NS 12 178  28 152  24 0.001 NYHA2, LVEF1 NS NS
Linde et al. (67) 2002 48 87% LBBB
Rest NS
12 176  19 156 (from figure
only)
0.05 NYHA2, LVEF1 NS NS
Lunati et al. (68) 2002 52 “Majority
LBBB”
12  5 194  33 159  19 0.0001 NYHA2, LVEF1 NS No
Pitzalis et al. (69) 2002 20 100% LBBB 1 169  16 132  12 0.0001 LVEF1, NYHA NS NS No
Reuter et al. (70) 2002 102 0% RBBB 12 184  38 168  25 0.01 NYHA2, LVEF1 No No
Ricci et al. (71) 2002 48 NS 9  4 154  29 120  18 0.001 NYHA2, LVEF1 NS NS
Continued on next page
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Table 3 Continued
Study Year
No. of
Patients*
Form of
Prolonged
QRS
Mean
Follow-Up
(months)
Mean QRS
Before CRT
(ms)
Mean QRS
After CRT
(ms)
Previous QRS vs.
QRS After CRT†
p Value
Clinical and
Hemodynamic
Improvement
Relationship
Between QRS
Shortening
and Clinical
Improvement
Correlation of
Spontaneous
QRS Duration
and Clinical
Response
Saxon et al. (72) 2002 53 63% LBBB
3% RBBB
34% Other
4 177  34 157  32 0.12 ns LVEF not1, LVEDD2,
LVEDD2, LVESV2,
NYHA NS
No No
Sogaard et al. (73) 2002 20 90% LBBB
10% RBBB
12.6 189  23 NS NS NYHA2, LVEF1 NS No
Yu et al. (74) 2002 25 NS 3 162  30 142  20 0.001 NYHA2, LVEF1 NS NS
Alonso et al. (75) 2001 102 NS 15  13 185  26 158  19 0.001 NYHA2, LVEF1 NS NS
Ansalone et al. (76) 2001 21 100% LBBB 1 week
and 1
month
158  31 122  27 0.00006 NYHA2, LVEF1 NS NS
Cazeau et al. (77) 2001 48 NS 3 174  20 157  30 0.002 NYHA NS, LVEF NS
QOL1, 6WD1
NS NS
Leclercq et al. (78) 2000 37
22, SR
15, AF
80% “LBBB
aspect”
20% PM
14  9 181  23 About 10%
reduction
NS NYHA2, LVEF1 only
in the AF group
NS NS
Leclercq et al. (79) 2000 50 40% PM 15  10 197  32 162  29 0.001 NYHA2 NS NS
Rest “LBBB
aspect”
LVEF1
Reuter et al. (80) 2000 47 NS 8 193  40 168  29 0.01 NYHA2, LVEF not 1 No NS
Toussaint et al. (81) 2000 21 NS 12 180 164 0.001 LVEF2, NYHA NS NS NS
Alonso et al. (82) 1999 26 88% LBBB
4% RBBB
8% IVCD
8  4 179  22‡ 154  17‡ 0.0004‡ NYHA2, LVEF NS Yes NS
Gras et al. (83) 1998 68 NS 3 179 143 0.001 NYHA2, LVEF not 1 No NS
*Studies with 20 patients; †p value comparing QRS duration before and after CRT; ‡p value is for the responder group (19 of 26 patients). There was no difference in QRS duration after CRT in the non-responder group (7 of 26
patients). Patients were not evaluated a single group. Acute studies are not included. Several articles in the Table provided no standard deviations on data.
AF  atrial fibrillation; CRT  cardiac resynchronization therapy; IVCD  intraventricular conduction delay; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; ms  milliseconds; No.  number; NS
 not stated; ns not statistically significant; NYHANew York Heart Association; PM previously implanted conventional pacemaker; pts patients; RBBB right bundle branch block; Vols volumes; Year year of publication.
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50 ms, and in 70% of patients with QRS 150 ms. Thus,
0% to 40% of patients with a wide QRS (predominantly
eflecting left-sided conduction delay) complex did not
how mechanical LV dyssynchrony, a figure that correlates
ith the reported percentage of nonresponders to CRT
elected on the basis of QRS duration. For this reason,
chocardiographic assessment with quantification of LV
yssynchrony is emerging as a superior predictor of CRT
utcome than the widened QRS complex (53–55,62,69,
3,85,86,89–91).
BBB. So far, the experience of CRT in a small number of
atients with RBBB and systolic HF is mixed, and it is likely
hat benefit may be restricted to patients with demonstrable
echanical LV dyssynchrony by echocardiography (92).
ARROW QRS COMPLEX <120 MS. It is possible that patients
ith HF with a narrow QRS complex (120 ms) may
enefit from CRT if they have echocardiographic mechan-
cal LV dyssynchrony. This question is presently under
ntensive clinical investigation (55,93).
RS NARROWING AFTER CARDIAC RESYNCHRONIZATION.
he paced QRS complex often narrows after resynchroni-
ation, but there is no correlation between QRS narrowing
nd the clinical response (Table 3). In some cases the QRS
omplex after CRT may actually lengthen or remain un-
hanged despite substantial improvement in mechanical LV
yssynchrony. Increased QRS duration with CRT does not
ecessarily reflect the presence of ventricular areas with slow
onduction resulting in more heterogeneous myocardial
ctivation. With mono-chamber LV pacing, there is an
bvious discrepancy between QRS duration (compared with
aseline) and hemodynamic and clinical improvement (94).
hus, in patients with HF, the paced QRS duration cannot
e assumed to reflect a more heterogeneous propagation
attern of LV activation and prolonged duration of me-
hanical activation.
ONCLUSIONS
wide QRS complex reflecting left-sided intraventricular
onduction delay in patients with HF is associated with
ore advanced myocardial disease, worse LV function,
oorer prognosis, and a higher all-cause mortality rate
ompared with patients with a narrow QRS complex. The
nfluence of a wide QRS complex on the incidence of
ardiac or sudden death is unclear because of limited
bservations. A progressive increase in QRS duration wors-
ns the prognosis. In patients with systolic HF, the presence
f a left-sided conduction delay alone can no longer be
utomatically equated with the presence of mechanical LV
yssynchrony, which is actually present in only about 70% of
ases. Mechanical LV dyssynchrony is best shown by
volving echocardiographic techniques (predominantly tis-
ue Doppler imaging) currently in the process of standard-
zation. Echocardiographic parameters will complement orven replace QRS complex duration as a criterion for CRT
atient selection. The duration of the basal QRS complex
oes not reliably predict the clinical response to ventricular
esynchronization, and QRS narrowing after CRT does not
orrelate with hemodynamic and clinical improvement.
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